ARA-290 (Cibinetide)

ARA-290 is the strongest peptide in this repair group on human-trial rigor, yet it is hemmed in by a narrow indication, small trials, no Phase 3, a defunct sponsor, and grey-market-only supply. The practical verdict splits by who you are. If you have refractory small-fiber neuropathy, especially sarcoidosis-associated or diabetic, this is the most evidence-backed peptide for that specific problem, with significant corneal nerve fiber regrowth at 4 mg per day, per Culver 2017, and a clean safety rationale. If you are stacking for general recovery or longevity, the score is generous: the proven benefit is narrow, broad claims are unproven, and you would be sourcing an investigational drug with no long-term human safety data. The score reflects that balance: real human RCTs pull it up, while the niche scope, small trial sizes, stalled development, and grey-market supply pull it back down. The design thesis is the safety story: because the protective and blood-raising effects of erythropoietin run through different receptors, a peptide aimed only at the repair receptor keeps the tissue protection and drops the clotting and red-blood-cell risk.Collino 2015, Pharmacol Ther

✅ Best for: People with refractory small-fiber neuropathy who have exhausted standard options and want the best-evidenced peptide for that niche. People with sarcoidosis-associated or diabetic neuropathic pain, the exact populations the trials studied, per Heij 2012. Those with the most severe small-fiber loss, who were the clearest responders in the diabetes Phase 2, per Brines 2015. Research-minded users who can work with a clinician, run baseline and follow-up monitoring, and verify material with a certificate of analysis. People who value a clean, non-erythropoietic safety rationale and a fully reversible profile.

❌ Avoid if: You have active or suspected cancer, since EPO-pathway-adjacent, tissue-growth-promoting agents are an unstudied risk in people. You are pregnant, breastfeeding, or considering it for a child, where no human safety data exists, per van Velzen 2014. You want general recovery, anti-inflammatory, or longevity benefits, which the human trials never demonstrated and a macular edema study failed to support, per Lois 2020. You cannot source verified, certificate-backed material, since the research-chemical market carries real purity and mislabeling risk. You want a proven, approved option, which this is not.